THERAPEUTIC ANTIBODY DISCOVERY
When tasked with difficult therapeutic targets (cell surface, multispanning transmembrane proteins, glycoproteins, etc.) there are a few things that make Abveris uniquely equipped to deliver with the best chance of success. This includes our comprehensive services, immunization expertise, and access to leading discovery platforms.
Work at Abveris is industry-leading as well as milestone and royalty-free!
SERVICES COMPLETS
PHASE PRÉCOCE
When working on unique targets, it may be difficult to find reliable reagents, namely proteins and/or cell lines. Our protein and cell line generation capabilities help to ensure that the appropriate amounts of immunization and screening materials are available. Once the project is complete, all remaining material are sent to our partners so that the materials can continue to be used as needed.
PHASE INTERMÉDIAIRE – RECHERCHE ET CRIBLAGE
Les procédés de criblage des lymphocytes B sur le système Beacon et de développement d’hybridome optimisé permettent la recherche de vastes ensembles variés d’AcM.
Avec notre gamme de plateformes haut débit de criblage et de caractérisation, nous pouvons non seulement identifier les liants idéaux, mais également cribler précocement dans le processus de recherche les anticorps de grande affinité et fonctionnels pertinents. La cytométrie en flux haut débit nous permet d’analyser la liaison aux cellules ainsi que l’activité fonctionnelle.
PHASE TARDIVE
Next-generation sequencing efforts are accompanied by custom data reports that highlight developability concerns and deliver more value. La production d’anticorps recombinants offre à nos partenaires la possibilité de produire de grandes quantités de leur anticorps favori dans une lignée cellulaire mammifère fiable.
EXPERTISE EN MATIÈRE D’IMMUNISATION
Abveris est fier de son expertise et de l’étendue de ses capacités d’immunisation. Les méthodes d’immunisation comportent les caractéristiques suivantes :
- À base de peptides/protéines
- À base de cellules
- Soustractives, à base de cellules
- À base d’ADN
- À base de particules pseudo-virales (VLP)
- Rupture de tolérance
The hyperimmune response of the DiversimAb mouse can generate appropriate titers in as little as 3 weeks, enabling rapid antibody discovery. Des adjuvants et des protocoles d’immunisation exclusifs permettent à notre équipe d’exploiter les caractéristiques hyperimmunes et auto-immunes de notre souche murine exclusive, pour améliorer encore la probabilité d’obtenir des ensembles d’anticorps variés et à réactivité croisée. Grâce à nos travaux sur différentes plateformes humanisées, nous avons optimisé nos méthodes d’immunisation pour les appliquer aux modèles murins couramment utilisés dans les campagnes de recherche thérapeutique.
PLATEFORMES DE RECHERCHE DE PREMIER PLAN
Abveris leverages a number of high throughput platforms for antibody screening and characterization. notamment des systèmes TECAN pour les analyses ELISA haut débit, la cytométrie en flux iQue pour le criblage cellulaire haut débit, le système de SPR de Carterra et Octet pour l’analyse de la cinétique des anticorps.
Our Toolbox
- Antigen and screening materials development
- Delivery of fully human mAbs using humanized mice from Alloy and Harbour
- Proprietary, hyper-immune DiversimAb mice to generate a more diverse mAb response than wild-type mice
- Multiple immunization techniques including: DNA immunization, cell immunization, rapid protocols, adjuvants to break tolerance and assist in cross-reactivity and more
- Highly efficient B cell screening (Beacon) and hybridoma approaches
- High-throughput, industry-leading screening tools to identify ideal mAbs including the iQue flow cytometer along with the Octet and Carterra systems for affinity, activity and epitope binning analysis.
- In-house sequencing capabilities
- Scale-up and purification of mAb from hybridoma or recombinantly
ANTI-IDIOTYPE ANTIBODY DISCOVERY
At Abveris, we deliver high-quality anti-idiotype antibodies using our DiversimAbTM platform. We apply stringent, high content screening in relevant formats predictive of downstream assay success to identify quality reagents for your specific drug development assays (e.g. PK and ADA).
- High-speed offerings
- 94% success-rate delivering on our partner's goals
- Stringent screening packages
- Diverse assay candidates delivered
Nous savons que ces AcM sont des outils essentiels pour le développement d’analyses cliniques, et la vitesse à laquelle nous livrons nos réactifs de grande qualité a en fin de compte un impact sur la vie des patients. Notre équipe est fière des travaux que nous réalisons et accorde la priorité à l’obtention d’anticorps de la meilleure qualité et dans des meilleurs délais du secteur pour appuyer vos essais cliniques.
CELL SURFACE TARGETING MABS
Our Secrets to Success
SELECT PROPER IMMUNOGENS
It is often challenging to present cell surface targets with proper conformation and post-translational modifications. Abveris applies innovative cell-based and DNA-based immunization protocols for cell surface immunogens to maintain the integrity of their complex structures. For certain targets and applications, recombinant proteins and peptide strategies may also provide value.
ABVERIS DIVERSIMAB™ TECHNOLOGY
The proprietary Abveris DiversimAb™ mouse provides the best in vivo option for generating monoclonal antibodies against membrane targets. DiversimAb™ technology can be applied to generate diverse panels of antibodies against tough targets, even when there are very few surface epitopes available. Abveris welcomes humanized mouse strains for fully human therapeutic antibody discovery, or knockout strains at the request of our partners.
HIGH-THROUGHPUT CELL BINDING ANALYSIS
The critical metric for success in antibody discovery for membrane targets is “on-cell binding,” thus necessitating frequent use of flow cytometry screening. The use of high-throughput flow cytometry technology unlocks the ability to screen massive panels of hybridomas with high resolution in hours instead of days.
REPERTOIRE MINING
Nature often has the superior power to utilize the diversity of immune repertoire to provide innovative insights into antibody engineering that rational design approaches may easily accomplish.
In conjunction with Abveris' proprietary hyperimmune mouse family (DievrsimAbTM Platform) and advanced screening technologies, the Hit Expansion Workflow offers opportunities to harness the power of natural repertoire diversity to expand the sequence space for rare, functionally-relevant hits, while increasing the success of antibody discovery against challenging therapeutic targets.
